longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

ACOTEC-B

06669

5.8200.26% ( -0.015 )
Delay Closed: Sep 14, 16:08:04
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -31.54, below the reasonable range, cheaper than 98.98% of the time in the past 3 years, and the industry ranks 28/32, the industry Median 9.39.

-31.54xP/E
HK$5.82Stock price
HK$-0.18Earnings per share
-31.54xP/E
Stock priceHK$5.82Earnings per shareHK$-0.18

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
56.57x
Typical range
34.27x–130.36x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 9.39x
012243648

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 9.39x
0x20x40x60x80x100x
P/E ratio
Name/Symbol
02526HKDIAGENS-B
-321.65x--HK$45.06B
02252HKMircroPort Medbot-B
-79.03x137.24%HK$21.84B
02675HKEDGE MEDICAL-B
-617.18x--HK$13.34B
02697HKTH MEDICAL-B
-86.15x--HK$9.30B
09996HKPEIJIA-B
-20.62x104.51%HK$3.35B
09877HKJENSCARE-B
-17.23x--HK$2.98B
06669HKACOTEC-B
-31.54x12.37%HK$1.82B
02160HKMP CARDIOFLOW-B
-11.13x94.94%HK$1.63B
06922HKCRYOFOCUS-B
-19.10x--HK$647.24M
02500HKVENUS MEDTECH-B
-0.95x100.95%HK$507.16M
02185HKBIOHEART-B
-4.65x--HK$404.07M
02216HKBRONCUS-B
-2.20x--HK$313.61M
02297HKRAINMED-B
-2.87x--HK$221.41M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.